Actively Recruiting
Palliative Steroeotactic Body Radiotherapy vs Palliative Standard Radiotherapy in Patients With Advanced Head and Neck Cancer
Led by Canadian Cancer Trials Group · Updated on 2026-05-12
196
Participants Needed
7
Research Sites
320 weeks
Total Duration
On this page
Sponsors
C
Canadian Cancer Trials Group
Lead Sponsor
C
Canadian Institutes of Health Research (CIHR)
Collaborating Sponsor
AI-Summary
What this Trial Is About
This study is being done to answer the following question: Does stereotactic body radiation therapy (SBRT) provide better cancer control compared to standard radiation therapy (RT) for those with advanced head and neck cancer?
CONDITIONS
Official Title
Palliative Steroeotactic Body Radiotherapy vs Palliative Standard Radiotherapy in Patients With Advanced Head and Neck Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Histologically confirmed mucosal squamous cell carcinoma of the head and neck from oro/hypopharynx, oral cavity, supraglottic larynx, maxillary sinus, nasal cavity, or unknown primary
- Stages TX or T0-T4/N0-N3
- Considered unfit for curative intent radiation therapy by treating oncologist(s)
- Geriatric 8 score less than 14
- At least 18 years of age
- Staging CT or MRI of head and neck within 8 weeks before randomization
- Chest CT or X-ray; PET CT allowed if diagnostic quality
- ECOG Performance Status 0 to 3
- Use of highly effective contraception if of childbearing potential
- Prior malignancy allowed if it does not interfere with safety or efficacy assessment
You will not qualify if you...
- Nasopharyngeal carcinoma
- Prior systemic therapy including immunotherapy
- Prior radiotherapy to head and neck except superficial skin cancer radiotherapy not overlapping current treatment
- Prior head and neck cancer excluding skin cancer
- Tumor locations or risks for SBRT toxicity including glottic/subglottic larynx, T4 hypopharynx, post-cricoid, cervical esophagus, circumferential pharyngeal involvement, extension near brain or optic structures, any tumor mass over 8 cm
- More than 2 nodal levels involved (Level 1a/b not counted); retropharyngeal lymph nodes less than 2 cm from treatment area not counted as different level
- Gross tumor poorly visible on CT or MRI
- Definite radiological or clinical distant metastases
- Scleroderma or CREST syndrome
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 7 locations
1
Arthur J.E. Child Comprehensive Cancer Centre
Calgary, Alberta, Canada, T2N 5G2
Actively Recruiting
2
Cross Cancer Institute
Edmonton, Alberta, Canada, T6G 1Z2
Actively Recruiting
3
CancerCare Manitoba
Winnipeg, Manitoba, Canada, R3E 0V9
Actively Recruiting
4
Ottawa Hospital Research Institute
Ottawa, Ontario, Canada, K1H 8L6
Actively Recruiting
5
Odette Cancer Centre
Toronto, Ontario, Canada, M4N 3M5
Actively Recruiting
6
University Health Network
Toronto, Ontario, Canada, M5G 2M9
Actively Recruiting
7
CHUM-Centre Hospitalier de l'Universite de Montreal
Montreal, Quebec, Canada, H2X 3E4
Actively Recruiting
Research Team
W
Wendy Parulekar
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here